April 23 (Reuters) - Wall Street's main indexes pared gains
sharply on Thursday, after a report that Gilead Sciences
experimental coronavirus drug flopped in its first randomized
clinical trial.
The Chinese trial showed that Gilead's GILD.O antiviral,
remdesivir, did not improve patients' condition or reduce the
pathogen's presence in the bloodstream, the Financial Times
reported, citing draft documents published accidentally by the
World Health Organization. At 12:51 a.m. ET the Dow Jones Industrial Average .DJI was
up 68.61 points, or 0.29%, at 23,544.43, the S&P 500 .SPX was
up 7.46 points, or 0.27%, at 2,806.77 and the Nasdaq Composite
.IXIC was up 33.58 points, or 0.40%, at 8,528.96.